Established and novel biologics – the therapeutic landscape is in flux

Clinically, atopic dermatitis (AD) manifests itself through a polymorphic picture of efflorescences, with pruritus and xerosis in the foreground. In addition to the antibody therapies dupilumab, tralokinumab and lebrikizumab, which target the IL-4/IL-13 signaling pathway, a fourth biologic, nemolizumab, is now available for the treatment of AD. The latter targets the IL-31 receptor, which mediates non-histaminergic itching. There are also promising findings from clinical studies on anti-OX40(L) antibodies.